- Coordinator
- Deutsches Krebsforschungszentrum Heidelberg, Germany
- Runs
- 1 February 2027 to 31 January 2032
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101300939
What the project is doing
In the project's own words, from its summary on CORDIS.
Immune cells, particularly cytotoxic T lymphocytes, are highly motile capable of infiltrating and eliminating tumors—a feature driving the recent revolution of immunotherapies. Yet a common barrier is the failure of T cells to infiltrate tumors, with local peritumoral and perivascular arrest as a key hurdle. Efforts to overcome this, such as decades of targeting of major tumor-supportive cytokines have yielded limited breakthroughs.
A likely reason is methodological bias: most studies profile bulk tissues at single endpoints, detecting only sustained, widespread signals while overlooking the transient, localized interactions that may drive T-cell arrest. I propose to develop spatially and temporally resolved transcriptomic technology to map immune cell interactions and behavior over time, and apply it to study immune dysfunction in glioblastoma (GBM), a lethal brain tumor.
I recently developed Zman-seq, the first in vivo single-cell method to capture immune cell state transitions over time and their driving signals. Zman-seq revealed that immune reprogramming occurs rapidly within just a day after infiltration. To resolve the early local interactions driving this, we will combine spatial data with Zman-seq, and measure T-cell motility as a functional readout. First, to pinpoint the early niches, I will combine Zman-seq timestamps with spatial transcriptomics and describe how immune cells occupy cellular niches over time.
Next, to study T-cell behavior within these niches, I will directly visualize T-cell motility via intravital microscopy and register in vivo tracks to ex vivo spatial transcriptomics, creating a new approach—VideoTranscriptomics. Applied in a GBM model, this will reveal the sequence of niches immune cells traverse, and pinpoint early, targetable checkpoints that drive T-cell arrest and immunotherapy resistance.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI